68 U.S. biotech / healthcare equity funds.
This list will be updated when there are notable fund closures or new launches. Updated as of 3/3/2026
8,000+ readers get my weekly insights on public equity research.
Methdology: additions and shutdowns are based on whether a fund appears as a Form ADV Part 2 filer (>$100M of regulatory AUM), compared to March 2025's data. 2026.3.8 New York City -6 shutdowns (all hedge funds): 2 activist, 1 growth, 1 value, 1 healthcare, 1
Estimated reading tie: ~10 minutes Continuing from last week's article, let's talk more tips on how you can become more effective as a junior sell-sider. Topics: * You don't get better as an investor on the sell-side, unless you want to * You need to own
Ron Baron Ronald Baron (b. 1943, Asbury Park, NJ) is an American billionaire mutual fund manager and the founder of Baron Capital, a growth-oriented investment firm that manages the Baron Funds. He earned a chemistry degree from Bucknell University before attending George Washington University Law School at night on scholarship.
If you’re a junior in sell-side equity research today, you’re entering at a strange time. The pay isn't what they used to be. Budgets are tighter, headcount is leaner, and senior analysts are being asked to do more with less. That tension shows up everywhere. And